nodes	percent_of_prediction	percent_of_DWPC	metapath
Halofantrine—CYP3A4—Thiotepa—urinary bladder cancer	0.127	0.256	CbGbCtD
Halofantrine—CYP2C8—Fluorouracil—urinary bladder cancer	0.102	0.205	CbGbCtD
Halofantrine—CYP3A5—Etoposide—urinary bladder cancer	0.0882	0.178	CbGbCtD
Halofantrine—CYP2C8—Etoposide—urinary bladder cancer	0.0848	0.171	CbGbCtD
Halofantrine—CYP2D6—Doxorubicin—urinary bladder cancer	0.0369	0.0743	CbGbCtD
Halofantrine—CYP3A4—Etoposide—urinary bladder cancer	0.0344	0.0693	CbGbCtD
Halofantrine—CYP3A4—Doxorubicin—urinary bladder cancer	0.0235	0.0473	CbGbCtD
Halofantrine—CYP2D6—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00626	0.0576	CbGpPWpGaD
Halofantrine—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.0041	0.0377	CbGpPWpGaD
Halofantrine—CYP2D6—Miscellaneous substrates—CYP4B1—urinary bladder cancer	0.00408	0.0375	CbGpPWpGaD
Halofantrine—CYP3A5—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00407	0.0374	CbGpPWpGaD
Halofantrine—KCNH2—Hematopoietic Stem Cell Differentiation—CSF3—urinary bladder cancer	0.00367	0.0338	CbGpPWpGaD
Halofantrine—CYP2C8—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00353	0.0324	CbGpPWpGaD
Halofantrine—CYP2D6—Fatty acids—CYP4B1—urinary bladder cancer	0.00341	0.0314	CbGpPWpGaD
Halofantrine—CYP3A5—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.0033	0.0304	CbGpPWpGaD
Halofantrine—CYP2D6—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00289	0.0266	CbGpPWpGaD
Halofantrine—CYP2C8—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00286	0.0263	CbGpPWpGaD
Halofantrine—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—urinary bladder cancer	0.00273	0.0251	CbGpPWpGaD
Halofantrine—CYP3A4—urine—urinary bladder cancer	0.00253	0.134	CbGeAlD
Halofantrine—CYP2D6—urine—urinary bladder cancer	0.00249	0.132	CbGeAlD
Halofantrine—CYP2D6—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00235	0.0216	CbGpPWpGaD
Halofantrine—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00214	0.0197	CbGpPWpGaD
Halofantrine—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00189	0.0174	CbGpPWpGaD
Halofantrine—Stomatitis—Cisplatin—urinary bladder cancer	0.00163	0.00433	CcSEcCtD
Halofantrine—Back pain—Thiotepa—urinary bladder cancer	0.00161	0.00428	CcSEcCtD
Halofantrine—Nausea—Mitomycin—urinary bladder cancer	0.0016	0.00427	CcSEcCtD
Halofantrine—CYP2C8—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00159	0.0146	CbGpPWpGaD
Halofantrine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00158	0.0146	CbGpPWpGaD
Halofantrine—Depressed level of consciousness—Methotrexate—urinary bladder cancer	0.00158	0.00421	CcSEcCtD
Halofantrine—CYP3A5—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00156	0.0144	CbGpPWpGaD
Halofantrine—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00153	0.0141	CbGpPWpGaD
Halofantrine—Stomatitis—Etoposide—urinary bladder cancer	0.00149	0.00396	CcSEcCtD
Halofantrine—KCNH2—prostate gland—urinary bladder cancer	0.00146	0.0778	CbGeAlD
Halofantrine—Pulmonary oedema—Methotrexate—urinary bladder cancer	0.00146	0.00388	CcSEcCtD
Halofantrine—Cough—Thiotepa—urinary bladder cancer	0.00145	0.00386	CcSEcCtD
Halofantrine—Visual impairment—Cisplatin—urinary bladder cancer	0.00144	0.00384	CcSEcCtD
Halofantrine—Chills—Gemcitabine—urinary bladder cancer	0.00144	0.00384	CcSEcCtD
Halofantrine—Convulsion—Thiotepa—urinary bladder cancer	0.00144	0.00383	CcSEcCtD
Halofantrine—Arrhythmia—Gemcitabine—urinary bladder cancer	0.00144	0.00382	CcSEcCtD
Halofantrine—Myalgia—Thiotepa—urinary bladder cancer	0.00142	0.00377	CcSEcCtD
Halofantrine—Arthralgia—Thiotepa—urinary bladder cancer	0.00142	0.00377	CcSEcCtD
Halofantrine—Arrhythmia—Fluorouracil—urinary bladder cancer	0.00141	0.00376	CcSEcCtD
Halofantrine—Tinnitus—Cisplatin—urinary bladder cancer	0.0014	0.00372	CcSEcCtD
Halofantrine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00137	0.0126	CbGpPWpGaD
Halofantrine—Confusional state—Thiotepa—urinary bladder cancer	0.00137	0.00364	CcSEcCtD
Halofantrine—Pulmonary oedema—Epirubicin—urinary bladder cancer	0.00136	0.00363	CcSEcCtD
Halofantrine—Back pain—Gemcitabine—urinary bladder cancer	0.00135	0.0036	CcSEcCtD
Halofantrine—CYP2C8—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00135	0.0124	CbGpPWpGaD
Halofantrine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00135	0.0124	CbGpPWpGaD
Halofantrine—Arrhythmia—Cisplatin—urinary bladder cancer	0.00134	0.00356	CcSEcCtD
Halofantrine—Abnormal vision—Epirubicin—urinary bladder cancer	0.00134	0.00355	CcSEcCtD
Halofantrine—Ill-defined disorder—Gemcitabine—urinary bladder cancer	0.0013	0.00345	CcSEcCtD
Halofantrine—Anorexia—Thiotepa—urinary bladder cancer	0.00129	0.00344	CcSEcCtD
Halofantrine—CYP3A5—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00128	0.0118	CbGpPWpGaD
Halofantrine—CYP3A5—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00128	0.0117	CbGpPWpGaD
Halofantrine—Malaise—Gemcitabine—urinary bladder cancer	0.00126	0.00336	CcSEcCtD
Halofantrine—Pulmonary oedema—Doxorubicin—urinary bladder cancer	0.00126	0.00336	CcSEcCtD
Halofantrine—KCNH2—seminal vesicle—urinary bladder cancer	0.00124	0.0658	CbGeAlD
Halofantrine—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00124	0.00329	CcSEcCtD
Halofantrine—Abnormal vision—Doxorubicin—urinary bladder cancer	0.00124	0.00329	CcSEcCtD
Halofantrine—Chills—Etoposide—urinary bladder cancer	0.00123	0.00328	CcSEcCtD
Halofantrine—Cough—Gemcitabine—urinary bladder cancer	0.00122	0.00325	CcSEcCtD
Halofantrine—Paraesthesia—Thiotepa—urinary bladder cancer	0.00122	0.00324	CcSEcCtD
Halofantrine—Cerebrovascular accident—Methotrexate—urinary bladder cancer	0.00121	0.00323	CcSEcCtD
Halofantrine—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.00121	0.00322	CcSEcCtD
Halofantrine—CYP3A5—prostate gland—urinary bladder cancer	0.00121	0.0642	CbGeAlD
Halofantrine—Dyspepsia—Thiotepa—urinary bladder cancer	0.0012	0.00318	CcSEcCtD
Halofantrine—Convulsion—Fluorouracil—urinary bladder cancer	0.00119	0.00317	CcSEcCtD
Halofantrine—Arthralgia—Gemcitabine—urinary bladder cancer	0.00119	0.00317	CcSEcCtD
Halofantrine—Myalgia—Gemcitabine—urinary bladder cancer	0.00119	0.00317	CcSEcCtD
Halofantrine—Chest pain—Gemcitabine—urinary bladder cancer	0.00119	0.00317	CcSEcCtD
Halofantrine—Decreased appetite—Thiotepa—urinary bladder cancer	0.00118	0.00314	CcSEcCtD
Halofantrine—Discomfort—Gemcitabine—urinary bladder cancer	0.00118	0.00313	CcSEcCtD
Halofantrine—Malaise—Cisplatin—urinary bladder cancer	0.00118	0.00313	CcSEcCtD
Halofantrine—Myalgia—Fluorouracil—urinary bladder cancer	0.00117	0.00312	CcSEcCtD
Halofantrine—Chest pain—Fluorouracil—urinary bladder cancer	0.00117	0.00312	CcSEcCtD
Halofantrine—Fatigue—Thiotepa—urinary bladder cancer	0.00117	0.00311	CcSEcCtD
Halofantrine—Constipation—Thiotepa—urinary bladder cancer	0.00116	0.00309	CcSEcCtD
Halofantrine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00116	0.0107	CbGpPWpGaD
Halofantrine—Discomfort—Fluorouracil—urinary bladder cancer	0.00116	0.00308	CcSEcCtD
Halofantrine—Back pain—Etoposide—urinary bladder cancer	0.00116	0.00307	CcSEcCtD
Halofantrine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00114	0.00304	CcSEcCtD
Halofantrine—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.00113	0.00302	CcSEcCtD
Halofantrine—Confusional state—Fluorouracil—urinary bladder cancer	0.00113	0.00301	CcSEcCtD
Halofantrine—Convulsion—Cisplatin—urinary bladder cancer	0.00113	0.00301	CcSEcCtD
Halofantrine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00113	0.0103	CbGpPWpGaD
Halofantrine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00112	0.00299	CcSEcCtD
Halofantrine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00112	0.00298	CcSEcCtD
Halofantrine—CYP2C8—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00111	0.0102	CbGpPWpGaD
Halofantrine—Myalgia—Cisplatin—urinary bladder cancer	0.00111	0.00295	CcSEcCtD
Halofantrine—CYP2D6—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00111	0.0102	CbGpPWpGaD
Halofantrine—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00111	0.00295	CcSEcCtD
Halofantrine—Ill-defined disorder—Etoposide—urinary bladder cancer	0.00111	0.00295	CcSEcCtD
Halofantrine—Discomfort—Cisplatin—urinary bladder cancer	0.0011	0.00292	CcSEcCtD
Halofantrine—Anorexia—Gemcitabine—urinary bladder cancer	0.00109	0.0029	CcSEcCtD
Halofantrine—Urticaria—Thiotepa—urinary bladder cancer	0.00108	0.00287	CcSEcCtD
Halofantrine—Malaise—Etoposide—urinary bladder cancer	0.00108	0.00287	CcSEcCtD
Halofantrine—Face oedema—Epirubicin—urinary bladder cancer	0.00107	0.00286	CcSEcCtD
Halofantrine—Abdominal pain—Thiotepa—urinary bladder cancer	0.00107	0.00285	CcSEcCtD
Halofantrine—Anorexia—Fluorouracil—urinary bladder cancer	0.00107	0.00285	CcSEcCtD
Halofantrine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00106	0.00283	CcSEcCtD
Halofantrine—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.00105	0.00279	CcSEcCtD
Halofantrine—Cough—Etoposide—urinary bladder cancer	0.00104	0.00277	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00104	0.00277	CcSEcCtD
Halofantrine—Convulsion—Etoposide—urinary bladder cancer	0.00104	0.00275	CcSEcCtD
Halofantrine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00103	0.00273	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00102	0.00272	CcSEcCtD
Halofantrine—Chest pain—Etoposide—urinary bladder cancer	0.00102	0.00271	CcSEcCtD
Halofantrine—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.00102	0.0027	CcSEcCtD
Halofantrine—Anorexia—Cisplatin—urinary bladder cancer	0.00101	0.0027	CcSEcCtD
Halofantrine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00101	0.00268	CcSEcCtD
Halofantrine—Discomfort—Etoposide—urinary bladder cancer	0.00101	0.00267	CcSEcCtD
Halofantrine—KCNH2—renal system—urinary bladder cancer	0.000997	0.053	CbGeAlD
Halofantrine—Face oedema—Doxorubicin—urinary bladder cancer	0.000994	0.00264	CcSEcCtD
Halofantrine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000993	0.00264	CcSEcCtD
Halofantrine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000988	0.00263	CcSEcCtD
Halofantrine—Fatigue—Gemcitabine—urinary bladder cancer	0.000985	0.00262	CcSEcCtD
Halofantrine—Confusional state—Etoposide—urinary bladder cancer	0.000983	0.00262	CcSEcCtD
Halofantrine—KCNH2—urethra—urinary bladder cancer	0.000979	0.0521	CbGeAlD
Halofantrine—Constipation—Gemcitabine—urinary bladder cancer	0.000977	0.0026	CcSEcCtD
Halofantrine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000976	0.0026	CcSEcCtD
Halofantrine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000975	0.00259	CcSEcCtD
Halofantrine—Asthenia—Thiotepa—urinary bladder cancer	0.000974	0.00259	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00097	0.00258	CcSEcCtD
Halofantrine—Abdominal distension—Epirubicin—urinary bladder cancer	0.000968	0.00257	CcSEcCtD
Halofantrine—Pruritus—Thiotepa—urinary bladder cancer	0.000961	0.00256	CcSEcCtD
Halofantrine—Paraesthesia—Cisplatin—urinary bladder cancer	0.000956	0.00254	CcSEcCtD
Halofantrine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000941	0.0025	CcSEcCtD
Halofantrine—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.00094	0.0025	CcSEcCtD
Halofantrine—Anorexia—Etoposide—urinary bladder cancer	0.00093	0.00247	CcSEcCtD
Halofantrine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000929	0.00247	CcSEcCtD
Halofantrine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000925	0.00246	CcSEcCtD
Halofantrine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000925	0.00246	CcSEcCtD
Halofantrine—CYP2C8—renal system—urinary bladder cancer	0.000912	0.0485	CbGeAlD
Halofantrine—CYP2D6—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000912	0.00839	CbGpPWpGaD
Halofantrine—Dizziness—Thiotepa—urinary bladder cancer	0.000898	0.00239	CcSEcCtD
Halofantrine—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000895	0.00238	CcSEcCtD
Halofantrine—Stomatitis—Methotrexate—urinary bladder cancer	0.000893	0.00237	CcSEcCtD
Halofantrine—Urticaria—Fluorouracil—urinary bladder cancer	0.000892	0.00237	CcSEcCtD
Halofantrine—Pollakiuria—Epirubicin—urinary bladder cancer	0.000888	0.00236	CcSEcCtD
Halofantrine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000877	0.00233	CcSEcCtD
Halofantrine—Paraesthesia—Etoposide—urinary bladder cancer	0.000876	0.00233	CcSEcCtD
Halofantrine—CYP3A5—Biological oxidations—GSTZ1—urinary bladder cancer	0.000873	0.00803	CbGpPWpGaD
Halofantrine—Vomiting—Thiotepa—urinary bladder cancer	0.000863	0.0023	CcSEcCtD
Halofantrine—CYP3A5—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000861	0.00792	CbGpPWpGaD
Halofantrine—Rash—Thiotepa—urinary bladder cancer	0.000856	0.00228	CcSEcCtD
Halofantrine—Dermatitis—Thiotepa—urinary bladder cancer	0.000855	0.00227	CcSEcCtD
Halofantrine—Headache—Thiotepa—urinary bladder cancer	0.00085	0.00226	CcSEcCtD
Halofantrine—Decreased appetite—Etoposide—urinary bladder cancer	0.000848	0.00226	CcSEcCtD
Halofantrine—CYP2C8—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000843	0.00776	CbGpPWpGaD
Halofantrine—Fatigue—Etoposide—urinary bladder cancer	0.000841	0.00224	CcSEcCtD
Halofantrine—Stomatitis—Epirubicin—urinary bladder cancer	0.000835	0.00222	CcSEcCtD
Halofantrine—Constipation—Etoposide—urinary bladder cancer	0.000834	0.00222	CcSEcCtD
Halofantrine—CYP3A5—Biological oxidations—GSTO2—urinary bladder cancer	0.000827	0.00761	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—NAT1—urinary bladder cancer	0.000827	0.00761	CbGpPWpGaD
Halofantrine—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000826	0.0076	CbGpPWpGaD
Halofantrine—CYP3A5—renal system—urinary bladder cancer	0.000823	0.0438	CbGeAlD
Halofantrine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000822	0.00219	CcSEcCtD
Halofantrine—Asthenia—Gemcitabine—urinary bladder cancer	0.000819	0.00218	CcSEcCtD
Halofantrine—CYP3A5—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000816	0.0075	CbGpPWpGaD
Halofantrine—Pruritus—Gemcitabine—urinary bladder cancer	0.000808	0.00215	CcSEcCtD
Halofantrine—Nausea—Thiotepa—urinary bladder cancer	0.000806	0.00215	CcSEcCtD
Halofantrine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000804	0.00214	CcSEcCtD
Halofantrine—KCNH2—female reproductive system—urinary bladder cancer	0.000799	0.0424	CbGeAlD
Halofantrine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000797	0.00212	CcSEcCtD
Halofantrine—Pruritus—Fluorouracil—urinary bladder cancer	0.000794	0.00211	CcSEcCtD
Halofantrine—Visual impairment—Methotrexate—urinary bladder cancer	0.000792	0.00211	CcSEcCtD
Halofantrine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000781	0.00208	CcSEcCtD
Halofantrine—Urticaria—Etoposide—urinary bladder cancer	0.000775	0.00206	CcSEcCtD
Halofantrine—Stomatitis—Doxorubicin—urinary bladder cancer	0.000773	0.00206	CcSEcCtD
Halofantrine—Abdominal pain—Etoposide—urinary bladder cancer	0.000771	0.00205	CcSEcCtD
Halofantrine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000768	0.00204	CcSEcCtD
Halofantrine—Tinnitus—Methotrexate—urinary bladder cancer	0.000767	0.00204	CcSEcCtD
Halofantrine—Asthenia—Cisplatin—urinary bladder cancer	0.000764	0.00203	CcSEcCtD
Halofantrine—CYP3A5—Biological oxidations—UGT2B7—urinary bladder cancer	0.000757	0.00696	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—GSTZ1—urinary bladder cancer	0.000756	0.00695	CbGpPWpGaD
Halofantrine—CYP3A5—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000746	0.00686	CbGpPWpGaD
Halofantrine—CYP2C8—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000746	0.00686	CbGpPWpGaD
Halofantrine—Dizziness—Fluorouracil—urinary bladder cancer	0.000743	0.00198	CcSEcCtD
Halofantrine—Visual impairment—Epirubicin—urinary bladder cancer	0.000741	0.00197	CcSEcCtD
Halofantrine—Chills—Methotrexate—urinary bladder cancer	0.000738	0.00196	CcSEcCtD
Halofantrine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000736	0.00676	CbGpPWpGaD
Halofantrine—CYP2C8—female reproductive system—urinary bladder cancer	0.000731	0.0388	CbGeAlD
Halofantrine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000728	0.00194	CcSEcCtD
Halofantrine—Vomiting—Gemcitabine—urinary bladder cancer	0.000726	0.00193	CcSEcCtD
Halofantrine—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000726	0.00668	CbGpPWpGaD
Halofantrine—KCNH2—vagina—urinary bladder cancer	0.000722	0.0384	CbGeAlD
Halofantrine—Rash—Gemcitabine—urinary bladder cancer	0.00072	0.00192	CcSEcCtD
Halofantrine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000719	0.00191	CcSEcCtD
Halofantrine—Tinnitus—Epirubicin—urinary bladder cancer	0.000717	0.00191	CcSEcCtD
Halofantrine—CYP2C8—Biological oxidations—GSTO2—urinary bladder cancer	0.000717	0.00659	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—NAT1—urinary bladder cancer	0.000717	0.00659	CbGpPWpGaD
Halofantrine—Headache—Gemcitabine—urinary bladder cancer	0.000715	0.0019	CcSEcCtD
Halofantrine—Vomiting—Fluorouracil—urinary bladder cancer	0.000714	0.0019	CcSEcCtD
Halofantrine—Rash—Fluorouracil—urinary bladder cancer	0.000708	0.00188	CcSEcCtD
Halofantrine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000707	0.00188	CcSEcCtD
Halofantrine—CYP2C8—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000707	0.0065	CbGpPWpGaD
Halofantrine—Headache—Fluorouracil—urinary bladder cancer	0.000703	0.00187	CcSEcCtD
Halofantrine—Asthenia—Etoposide—urinary bladder cancer	0.0007	0.00186	CcSEcCtD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.000694	0.00638	CbGpPWpGaD
Halofantrine—Back pain—Methotrexate—urinary bladder cancer	0.000692	0.00184	CcSEcCtD
Halofantrine—Chills—Epirubicin—urinary bladder cancer	0.00069	0.00184	CcSEcCtD
Halofantrine—Pruritus—Etoposide—urinary bladder cancer	0.00069	0.00184	CcSEcCtD
Halofantrine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000687	0.00183	CcSEcCtD
Halofantrine—Visual impairment—Doxorubicin—urinary bladder cancer	0.000686	0.00183	CcSEcCtD
Halofantrine—CYP3A5—Biological oxidations—CYP4B1—urinary bladder cancer	0.000681	0.00627	CbGpPWpGaD
Halofantrine—Nausea—Gemcitabine—urinary bladder cancer	0.000678	0.0018	CcSEcCtD
Halofantrine—Vomiting—Cisplatin—urinary bladder cancer	0.000677	0.0018	CcSEcCtD
Halofantrine—CYP3A5—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000672	0.00618	CbGpPWpGaD
Halofantrine—Rash—Cisplatin—urinary bladder cancer	0.000671	0.00179	CcSEcCtD
Halofantrine—Dermatitis—Cisplatin—urinary bladder cancer	0.000671	0.00178	CcSEcCtD
Halofantrine—Diarrhoea—Etoposide—urinary bladder cancer	0.000667	0.00177	CcSEcCtD
Halofantrine—Nausea—Fluorouracil—urinary bladder cancer	0.000667	0.00177	CcSEcCtD
Halofantrine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000664	0.00177	CcSEcCtD
Halofantrine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000664	0.00177	CcSEcCtD
Halofantrine—CYP2C8—vagina—urinary bladder cancer	0.000661	0.0351	CbGeAlD
Halofantrine—CYP2C8—Biological oxidations—UGT2B7—urinary bladder cancer	0.000655	0.00603	CbGpPWpGaD
Halofantrine—Back pain—Epirubicin—urinary bladder cancer	0.000648	0.00172	CcSEcCtD
Halofantrine—CYP2C8—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000646	0.00595	CbGpPWpGaD
Halofantrine—Malaise—Methotrexate—urinary bladder cancer	0.000645	0.00172	CcSEcCtD
Halofantrine—Dizziness—Etoposide—urinary bladder cancer	0.000645	0.00172	CcSEcCtD
Halofantrine—Chills—Doxorubicin—urinary bladder cancer	0.000639	0.0017	CcSEcCtD
Halofantrine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000636	0.00169	CcSEcCtD
Halofantrine—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000633	0.00582	CbGpPWpGaD
Halofantrine—Nausea—Cisplatin—urinary bladder cancer	0.000632	0.00168	CcSEcCtD
Halofantrine—Cough—Methotrexate—urinary bladder cancer	0.000625	0.00166	CcSEcCtD
Halofantrine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000621	0.00165	CcSEcCtD
Halofantrine—CYP2D6—Biological oxidations—GSTZ1—urinary bladder cancer	0.000621	0.00571	CbGpPWpGaD
Halofantrine—Convulsion—Methotrexate—urinary bladder cancer	0.00062	0.00165	CcSEcCtD
Halofantrine—Vomiting—Etoposide—urinary bladder cancer	0.00062	0.00165	CcSEcCtD
Halofantrine—CYP3A4—renal system—urinary bladder cancer	0.000618	0.0328	CbGeAlD
Halofantrine—Rash—Etoposide—urinary bladder cancer	0.000615	0.00164	CcSEcCtD
Halofantrine—Dermatitis—Etoposide—urinary bladder cancer	0.000614	0.00163	CcSEcCtD
Halofantrine—CYP2D6—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000612	0.00563	CbGpPWpGaD
Halofantrine—Headache—Etoposide—urinary bladder cancer	0.000611	0.00163	CcSEcCtD
Halofantrine—Myalgia—Methotrexate—urinary bladder cancer	0.000609	0.00162	CcSEcCtD
Halofantrine—Chest pain—Methotrexate—urinary bladder cancer	0.000609	0.00162	CcSEcCtD
Halofantrine—Arthralgia—Methotrexate—urinary bladder cancer	0.000609	0.00162	CcSEcCtD
Halofantrine—CYP2D6—renal system—urinary bladder cancer	0.000608	0.0323	CbGeAlD
Halofantrine—Malaise—Epirubicin—urinary bladder cancer	0.000604	0.00161	CcSEcCtD
Halofantrine—Discomfort—Methotrexate—urinary bladder cancer	0.000602	0.0016	CcSEcCtD
Halofantrine—Back pain—Doxorubicin—urinary bladder cancer	0.000599	0.00159	CcSEcCtD
Halofantrine—CYP3A5—vagina—urinary bladder cancer	0.000596	0.0317	CbGeAlD
Halofantrine—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000596	0.00548	CbGpPWpGaD
Halofantrine—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000594	0.00546	CbGpPWpGaD
Halofantrine—Palpitations—Epirubicin—urinary bladder cancer	0.000592	0.00157	CcSEcCtD
Halofantrine—CYP2C8—Biological oxidations—CYP4B1—urinary bladder cancer	0.00059	0.00543	CbGpPWpGaD
Halofantrine—Confusional state—Methotrexate—urinary bladder cancer	0.000589	0.00157	CcSEcCtD
Halofantrine—CYP2D6—Biological oxidations—GSTO2—urinary bladder cancer	0.000588	0.00541	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—NAT1—urinary bladder cancer	0.000588	0.00541	CbGpPWpGaD
Halofantrine—Cough—Epirubicin—urinary bladder cancer	0.000584	0.00155	CcSEcCtD
Halofantrine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000584	0.00155	CcSEcCtD
Halofantrine—CYP2C8—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000582	0.00535	CbGpPWpGaD
Halofantrine—Convulsion—Epirubicin—urinary bladder cancer	0.00058	0.00154	CcSEcCtD
Halofantrine—CYP2D6—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00058	0.00534	CbGpPWpGaD
Halofantrine—Nausea—Etoposide—urinary bladder cancer	0.000579	0.00154	CcSEcCtD
Halofantrine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000575	0.00153	CcSEcCtD
Halofantrine—Arthralgia—Epirubicin—urinary bladder cancer	0.00057	0.00152	CcSEcCtD
Halofantrine—Chest pain—Epirubicin—urinary bladder cancer	0.00057	0.00152	CcSEcCtD
Halofantrine—Myalgia—Epirubicin—urinary bladder cancer	0.00057	0.00152	CcSEcCtD
Halofantrine—Discomfort—Epirubicin—urinary bladder cancer	0.000563	0.0015	CcSEcCtD
Halofantrine—Malaise—Doxorubicin—urinary bladder cancer	0.000559	0.00149	CcSEcCtD
Halofantrine—Anorexia—Methotrexate—urinary bladder cancer	0.000557	0.00148	CcSEcCtD
Halofantrine—Confusional state—Epirubicin—urinary bladder cancer	0.000551	0.00147	CcSEcCtD
Halofantrine—Palpitations—Doxorubicin—urinary bladder cancer	0.000548	0.00146	CcSEcCtD
Halofantrine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000547	0.00145	CcSEcCtD
Halofantrine—Cough—Doxorubicin—urinary bladder cancer	0.000541	0.00144	CcSEcCtD
Halofantrine—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	0.000538	0.00495	CbGpPWpGaD
Halofantrine—Convulsion—Doxorubicin—urinary bladder cancer	0.000537	0.00143	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000532	0.00142	CcSEcCtD
Halofantrine—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000531	0.00488	CbGpPWpGaD
Halofantrine—Chest pain—Doxorubicin—urinary bladder cancer	0.000528	0.0014	CcSEcCtD
Halofantrine—Myalgia—Doxorubicin—urinary bladder cancer	0.000528	0.0014	CcSEcCtD
Halofantrine—Arthralgia—Doxorubicin—urinary bladder cancer	0.000528	0.0014	CcSEcCtD
Halofantrine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000525	0.0014	CcSEcCtD
Halofantrine—Discomfort—Doxorubicin—urinary bladder cancer	0.000521	0.00139	CcSEcCtD
Halofantrine—Anorexia—Epirubicin—urinary bladder cancer	0.000521	0.00139	CcSEcCtD
Halofantrine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000514	0.00137	CcSEcCtD
Halofantrine—Confusional state—Doxorubicin—urinary bladder cancer	0.00051	0.00136	CcSEcCtD
Halofantrine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000508	0.00135	CcSEcCtD
Halofantrine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000506	0.00135	CcSEcCtD
Halofantrine—Fatigue—Methotrexate—urinary bladder cancer	0.000504	0.00134	CcSEcCtD
Halofantrine—CYP2C8—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000499	0.00459	CbGpPWpGaD
Halofantrine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000498	0.00132	CcSEcCtD
Halofantrine—CYP3A4—female reproductive system—urinary bladder cancer	0.000495	0.0263	CbGeAlD
Halofantrine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000491	0.00131	CcSEcCtD
Halofantrine—CYP2D6—female reproductive system—urinary bladder cancer	0.000487	0.0259	CbGeAlD
Halofantrine—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.000484	0.00446	CbGpPWpGaD
Halofantrine—Anorexia—Doxorubicin—urinary bladder cancer	0.000482	0.00128	CcSEcCtD
Halofantrine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000481	0.00128	CcSEcCtD
Halofantrine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000481	0.00128	CcSEcCtD
Halofantrine—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000478	0.00439	CbGpPWpGaD
Halofantrine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000478	0.00127	CcSEcCtD
Halofantrine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000475	0.00126	CcSEcCtD
Halofantrine—Fatigue—Epirubicin—urinary bladder cancer	0.000471	0.00125	CcSEcCtD
Halofantrine—Constipation—Epirubicin—urinary bladder cancer	0.000467	0.00124	CcSEcCtD
Halofantrine—KCNH2—lymph node—urinary bladder cancer	0.000467	0.0248	CbGeAlD
Halofantrine—Urticaria—Methotrexate—urinary bladder cancer	0.000464	0.00123	CcSEcCtD
Halofantrine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000462	0.00123	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000461	0.00123	CcSEcCtD
Halofantrine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000454	0.00121	CcSEcCtD
Halofantrine—CYP3A5—Biological oxidations—NAT2—urinary bladder cancer	0.000453	0.00417	CbGpPWpGaD
Halofantrine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00045	0.0012	CcSEcCtD
Halofantrine—CYP3A5—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000447	0.00411	CbGpPWpGaD
Halofantrine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000447	0.00119	CcSEcCtD
Halofantrine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000445	0.00118	CcSEcCtD
Halofantrine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.00044	0.00117	CcSEcCtD
Halofantrine—Fatigue—Doxorubicin—urinary bladder cancer	0.000436	0.00116	CcSEcCtD
Halofantrine—Urticaria—Epirubicin—urinary bladder cancer	0.000434	0.00116	CcSEcCtD
Halofantrine—Constipation—Doxorubicin—urinary bladder cancer	0.000433	0.00115	CcSEcCtD
Halofantrine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000432	0.00115	CcSEcCtD
Halofantrine—Asthenia—Methotrexate—urinary bladder cancer	0.000419	0.00111	CcSEcCtD
Halofantrine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000417	0.00111	CcSEcCtD
Halofantrine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000414	0.0011	CcSEcCtD
Halofantrine—Pruritus—Methotrexate—urinary bladder cancer	0.000413	0.0011	CcSEcCtD
Halofantrine—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000406	0.00373	CbGpPWpGaD
Halofantrine—Urticaria—Doxorubicin—urinary bladder cancer	0.000402	0.00107	CcSEcCtD
Halofantrine—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.0004	0.00368	CbGpPWpGaD
Halofantrine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.0004	0.00106	CcSEcCtD
Halofantrine—Diarrhoea—Methotrexate—urinary bladder cancer	0.0004	0.00106	CcSEcCtD
Halofantrine—CYP2C8—Biological oxidations—NAT2—urinary bladder cancer	0.000393	0.00361	CbGpPWpGaD
Halofantrine—Asthenia—Epirubicin—urinary bladder cancer	0.000392	0.00104	CcSEcCtD
Halofantrine—CYP2C8—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000387	0.00356	CbGpPWpGaD
Halofantrine—Pruritus—Epirubicin—urinary bladder cancer	0.000387	0.00103	CcSEcCtD
Halofantrine—Dizziness—Methotrexate—urinary bladder cancer	0.000386	0.00103	CcSEcCtD
Halofantrine—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000385	0.00354	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000385	0.00354	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000379	0.00349	CbGpPWpGaD
Halofantrine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000374	0.000995	CcSEcCtD
Halofantrine—Vomiting—Methotrexate—urinary bladder cancer	0.000371	0.000988	CcSEcCtD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000369	0.00339	CbGpPWpGaD
Halofantrine—Rash—Methotrexate—urinary bladder cancer	0.000368	0.00098	CcSEcCtD
Halofantrine—Dermatitis—Methotrexate—urinary bladder cancer	0.000368	0.000979	CcSEcCtD
Halofantrine—Headache—Methotrexate—urinary bladder cancer	0.000366	0.000973	CcSEcCtD
Halofantrine—Asthenia—Doxorubicin—urinary bladder cancer	0.000363	0.000965	CcSEcCtD
Halofantrine—CYP3A5—Biological oxidations—HPGDS—urinary bladder cancer	0.000362	0.00333	CbGpPWpGaD
Halofantrine—Dizziness—Epirubicin—urinary bladder cancer	0.000361	0.000962	CcSEcCtD
Halofantrine—Pruritus—Doxorubicin—urinary bladder cancer	0.000358	0.000952	CcSEcCtD
Halofantrine—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000352	0.00324	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—GSTT1—urinary bladder cancer	0.000352	0.00323	CbGpPWpGaD
Halofantrine—Vomiting—Epirubicin—urinary bladder cancer	0.000348	0.000925	CcSEcCtD
Halofantrine—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000347	0.00319	CbGpPWpGaD
Halofantrine—Nausea—Methotrexate—urinary bladder cancer	0.000347	0.000923	CcSEcCtD
Halofantrine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000346	0.000921	CcSEcCtD
Halofantrine—Rash—Epirubicin—urinary bladder cancer	0.000345	0.000917	CcSEcCtD
Halofantrine—Dermatitis—Epirubicin—urinary bladder cancer	0.000344	0.000916	CcSEcCtD
Halofantrine—Headache—Epirubicin—urinary bladder cancer	0.000342	0.000911	CcSEcCtD
Halofantrine—Dizziness—Doxorubicin—urinary bladder cancer	0.000334	0.00089	CcSEcCtD
Halofantrine—Nausea—Epirubicin—urinary bladder cancer	0.000325	0.000864	CcSEcCtD
Halofantrine—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000322	0.00296	CbGpPWpGaD
Halofantrine—Vomiting—Doxorubicin—urinary bladder cancer	0.000322	0.000855	CcSEcCtD
Halofantrine—Rash—Doxorubicin—urinary bladder cancer	0.000319	0.000848	CcSEcCtD
Halofantrine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000319	0.000848	CcSEcCtD
Halofantrine—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000318	0.00292	CbGpPWpGaD
Halofantrine—Headache—Doxorubicin—urinary bladder cancer	0.000317	0.000843	CcSEcCtD
Halofantrine—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000317	0.00291	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—HPGDS—urinary bladder cancer	0.000314	0.00289	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000312	0.00287	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—GSTT1—urinary bladder cancer	0.000304	0.0028	CbGpPWpGaD
Halofantrine—Nausea—Doxorubicin—urinary bladder cancer	0.0003	0.000799	CcSEcCtD
Halofantrine—CYP2C8—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000294	0.0027	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000293	0.00269	CbGpPWpGaD
Halofantrine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000273	0.00251	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000258	0.00237	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000251	0.00231	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.00025	0.0023	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—GSTP1—urinary bladder cancer	0.000244	0.00224	CbGpPWpGaD
Halofantrine—CYP3A5—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.00024	0.00221	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000227	0.00208	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—GSTM1—urinary bladder cancer	0.000224	0.00206	CbGpPWpGaD
Halofantrine—CYP3A5—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000221	0.00203	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—GSTP1—urinary bladder cancer	0.000211	0.00194	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000211	0.00194	CbGpPWpGaD
Halofantrine—CYP2C8—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000208	0.00191	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000208	0.00191	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000204	0.00188	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—GSTM1—urinary bladder cancer	0.000194	0.00178	CbGpPWpGaD
Halofantrine—CYP2C8—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000191	0.00176	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000173	0.00159	CbGpPWpGaD
Halofantrine—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000171	0.00157	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000168	0.00155	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000163	0.0015	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.000159	0.00146	CbGpPWpGaD
Halofantrine—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000157	0.00144	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	0.000149	0.00137	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	0.000141	0.0013	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—NAT1—urinary bladder cancer	0.000141	0.0013	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	0.000129	0.00119	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	0.000129	0.00119	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	0.000123	0.00113	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—NAT1—urinary bladder cancer	0.000123	0.00113	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000121	0.00111	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	0.000117	0.00107	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.000113	0.00104	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	0.000112	0.00103	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000112	0.00103	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	0.00011	0.00101	CbGpPWpGaD
Halofantrine—KCNH2—Neuronal System—HRAS—urinary bladder cancer	0.000108	0.000993	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	0.000107	0.000986	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	0.000106	0.000976	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000104	0.000957	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000103	0.000944	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	0.000101	0.000928	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	0.000101	0.000925	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—NAT1—urinary bladder cancer	0.000101	0.000925	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	9.53e-05	0.000877	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	9.29e-05	0.000854	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	9.2e-05	0.000846	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—TYMP—urinary bladder cancer	8.57e-05	0.000788	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	8.29e-05	0.000762	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	7.82e-05	0.00072	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—NAT2—urinary bladder cancer	7.75e-05	0.000713	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	7.63e-05	0.000701	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	7.45e-05	0.000685	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—TYMP—urinary bladder cancer	7.43e-05	0.000683	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.13e-05	0.000656	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	6.94e-05	0.000638	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—NAT2—urinary bladder cancer	6.72e-05	0.000618	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—RRM2—urinary bladder cancer	6.69e-05	0.000615	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	6.58e-05	0.000605	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	6.58e-05	0.000605	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	6.2e-05	0.00057	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ENO2—urinary bladder cancer	6.2e-05	0.00057	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	6.1e-05	0.000561	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	6.02e-05	0.000553	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	6.01e-05	0.000553	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—RRM2—urinary bladder cancer	5.8e-05	0.000533	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	5.51e-05	0.000507	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	5.42e-05	0.000498	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	5.37e-05	0.000494	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ENO2—urinary bladder cancer	5.37e-05	0.000494	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.34e-05	0.000491	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	5.21e-05	0.000479	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.13e-05	0.000471	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	5.12e-05	0.00047	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—NQO1—urinary bladder cancer	5e-05	0.000459	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	4.99e-05	0.000458	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	4.76e-05	0.000438	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	4.41e-05	0.000405	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	4.41e-05	0.000405	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—NQO1—urinary bladder cancer	4.33e-05	0.000398	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	4.27e-05	0.000393	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.2e-05	0.000386	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	4.17e-05	0.000383	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.99e-05	0.000367	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—TYMS—urinary bladder cancer	3.87e-05	0.000356	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	3.83e-05	0.000352	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	3.83e-05	0.000352	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GPX1—urinary bladder cancer	3.67e-05	0.000337	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.66e-05	0.000337	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	3.61e-05	0.000332	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	3.6e-05	0.000331	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	3.6e-05	0.000331	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	3.55e-05	0.000327	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.49e-05	0.000321	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	3.38e-05	0.000311	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—TYMS—urinary bladder cancer	3.36e-05	0.000309	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	3.32e-05	0.000305	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	3.32e-05	0.000305	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GPX1—urinary bladder cancer	3.18e-05	0.000292	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	3.12e-05	0.000287	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.11e-05	0.000286	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.96e-05	0.000272	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	2.93e-05	0.00027	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.88e-05	0.000265	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.88e-05	0.000265	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.79e-05	0.000257	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.75e-05	0.000253	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PPARG—urinary bladder cancer	2.74e-05	0.000252	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.72e-05	0.00025	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.72e-05	0.00025	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	2.64e-05	0.000242	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.61e-05	0.00024	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.56e-05	0.000235	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2.41e-05	0.000221	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PPARG—urinary bladder cancer	2.38e-05	0.000219	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.32e-05	0.000214	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	2.28e-05	0.00021	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	2.16e-05	0.000199	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.95e-05	0.000179	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.94e-05	0.000178	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PTEN—urinary bladder cancer	1.88e-05	0.000173	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.87e-05	0.000172	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.87e-05	0.000172	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.8e-05	0.000166	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—EP300—urinary bladder cancer	1.8e-05	0.000165	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.78e-05	0.000164	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.78e-05	0.000164	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.7e-05	0.000157	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.67e-05	0.000154	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.63e-05	0.00015	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.57e-05	0.000145	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.56e-05	0.000143	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.53e-05	0.000141	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.34e-05	0.000123	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.28e-05	0.000117	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.28e-05	0.000117	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.23e-05	0.000113	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1e-05	9.23e-05	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	8.75e-06	8.05e-05	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—EP300—urinary bladder cancer	8.35e-06	7.68e-05	CbGpPWpGaD
